Naratriptan indications and usage

Revision as of 20:00, 3 February 2014 by Gerald Chi (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Naratriptan
NARATRIPTAN tablet® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Naratriptan
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Indications and Usage

Naratriptan tablets, USP are indicated for the acute treatment of migraine attacks with or without aura in adults.

Naratriptan tablets, USP are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS). Safety and effectiveness of naratriptan tablets, USP have not been established for cluster headache, which is present in an older, predominantly male population.[1]

References

  1. "NARATRIPTAN TABLET, COATED [SANDOZ INC]".

Adapted from the FDA Package Insert.

Template:Antimigraine preparations